Recombinant Super-Compound Interferon (rSIFN-co) Versus Interferon Alfa in the Treatment of Moderate-to-Severe COVID-19: A Multicentre, Randomised, Phase 2 Trial

Authors :: Nian Xiong
Jia Zeng
Lunxu Liu
Haiyan Liu
Chengwu Liu
Wei Zhang
Zhihua Xu
Duo Li
Chuan Li
Fengming Luo
Zhen Zeng
Yuanhong He
Senyi Deng
Weiming Li
Ye Wang
Meng Duan
Mei Feng
Li Zhang
Ming Yang
Dan Liu
Jiandong Mei
Zhengyu Shi
Chao Yu
Jiayu Liao
Yanbin Liu
Deying Kang
Ruoyang Liu
Source :: SSRN Electronic Journal.
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Moderate to severe
Pneumonia
Coronavirus disease 2019 (COVID-19)
Interferon
business.industry
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
medicine
Recombinant Super-compound Interferon
medicine.disease
business
Virology
Interferon alfa
medicine.drug

Full Text Access

Tools